Diabetes drug may shield heart nerves from damage
NCT ID NCT07558863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether GLP-1 receptor agonists, a class of diabetes medications including semaglutide, can improve heart nerve damage in people with type 2 diabetes. 60 adults will receive either standard care or standard care plus a weekly injection for 6 months. Researchers will measure heart rate variability and other heart function tests to see if the drug helps protect the heart's nerves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonists (semaglutide or polyethylene glycol loxenatide)
What this could lead to
If it works, this could show that GLP-1 drugs protect against or improve diabetic heart nerve damage, reducing risks of heart attack and sudden death.
What could go wrong
This is a small, early-phase study with only 60 participants. Results may not apply to everyone, and the treatment may not improve nerve function beyond standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••